source
- Merck wins FDA nod for first oral PCSK9 inhibitor, Lipfendra, to treat high LDL cholesterolMerck announced that the U.S. Food and Drug Administration has approved its once-daily oral PCSK9 inhibitor, enlicitide, marketed as Lipfendra, for adults with elevated LDL cholesterol. The drug i…
- Eli Lilly to acquire AtaiBeckley in up to $3.8 billion deal, entering psychedelics marketEli Lilly announced it will buy AtaiBeckley, offering $6.75 per share for the company’s common stock. The transaction includes an upfront commitment of about $2.8 billion and a contingent value rig…